Literature DB >> 12594116

Filaggrin related antibodies among the aged.

T Palosuo1, R Tilvis, T Strandberg, K Aho.   

Abstract

BACKGROUND: The mean age at onset of new cases of rheumatoid arthritis (RA) has increased markedly. Because the prevalence of false positive rheumatoid factor reactions increases with advancing age, the diagnostic value of this test has limitations among the aged.
OBJECTIVE: To study the occurrence of two filaggrin related antibodies in an aged population.
METHODS: The study covered 300 subjects aged 78-88 years, one of whom had RA. The sera were tested with enzyme linked immunosorbent assays (ELISAs), using filaggrin purified from human skin and citrullinated cyclic peptide (CCP) as antigens.
RESULTS: One patient with RA was positive for both antibodies. When the cut off level for positive reactions was set at the 98th centile of healthy blood donors, 24 (8%) of the other subjects were positive for antibodies against filaggrin, but only one against CCP.
CONCLUSION: The test for anti-CCP antibody has better specificity than the test for antibodies against filaggrin among the aged.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594116      PMCID: PMC1754464          DOI: 10.1136/ard.62.3.261

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis.

Authors:  Nehir Samanci; Sebahat Ozdem; Halide Akbas; Derya Mutlu; Meral Gultekin; Mehmet Arman; Levent Donmez
Journal:  J Natl Med Assoc       Date:  2005-08       Impact factor: 1.798

2.  Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX™: planar microarray diagnosis.

Authors:  Peter Lea; Edward Keystone; Sasi Mudumba; Anthony Kahama; Shi-Fa Ding; Jennifer Hansen; Azar A Azad; Sihe Wang; Deborah Weber
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

3.  The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.

Authors:  Ct Chou; Ht Liao; Ch Chen; Ws Chen; Hp Wang; Ky Su
Journal:  Biomark Insights       Date:  2007-05-03

4.  Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy.

Authors:  Wafaa M Ezzat; Hala M Raslan; Azza A Aly; Nahed A Emara; Manal M El Menyawi; Amr Edrees
Journal:  Rheumatol Int       Date:  2009-11-01       Impact factor: 2.631

Review 5.  Update on autoantibodies in rheumatoid arthritis.

Authors:  S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 6.  Anti-citrullinated protein antibodies: role in pathogenesis of RA and potential as a diagnostic tool.

Authors:  Sadaf Moeez; Peter John; Attya Bhatti
Journal:  Rheumatol Int       Date:  2013-02-01       Impact factor: 2.631

7.  Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis.

Authors:  D S Majka; K D Deane; L A Parrish; A A Lazar; A E Barón; C W Walker; M V Rubertone; W R Gilliland; J M Norris; V M Holers
Journal:  Ann Rheum Dis       Date:  2007-11-01       Impact factor: 19.103

8.  Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages.

Authors:  E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

9.  Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases.

Authors:  S Dubucquoi; E Solau-Gervais; D Lefranc; L Marguerie; J Sibilia; J Goetz; V Dutoit; A-L Fauchais; E Hachulla; R-M Flipo; L Prin
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

10.  Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems.

Authors:  Jennie Ursum; Wouter H Bos; Rob J van de Stadt; Ben A C Dijkmans; Dirkjan van Schaardenburg
Journal:  Arthritis Res Ther       Date:  2009-05-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.